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ABSTRACT: Adjuvants are components of vaccine that enhance the
specific immune response against co-inoculated antigens. Recently, we
reported the characterization of a synthetic sulfolipid named Sulfavant
A (1) as a promising candidate of a novel class of molecular adjuvants
based on the sulfoquinovosyl-diacylglycerol skeleton. Here, we report
an improved synthesis of the sulfolipid scaffold, as well as the
preparation of two analogs named Sulfavant-S (2) and Sulfavant-R (3)
with enhanced property to modulate master immune targets such as
human dendritic cells (DCs). According to the present approach,
synthesis of 1 is reduced from 14 to 11 steps with nearly triplication of
the overall yield (11%). The new members 2 and 3 elicit DC
maturation at a concentration of 10 nM, which is 1000 times more
potent than the parent molecule 1. Analysis of dynamic light scattering
indicates self-assembly of Sulfavants and formation of colloidal
particles with a small hydrodynamic radius (50 nm) for the epimers 2 and 3 and a larger radius (150 nm) for 1. The
colloidal aggregates are responsible for the bell-shaped dose−response curve of these products. We conclude that the particle
size also affects the equilibrium with free monomers, thus determining the effective concentration of the sulfolipid molecule at
the cellular targets and the different immunological efficacy of 1−3. Sulfavants (1−3) do not show in vitro cytotoxicity at
concentrations 105 higher than the dose that triggers maximal immune response, thus predicting a low level of toxicological risk
in their formulation in vaccines.
■ INTRODUCTION
Adjuvants are aspecific components of vaccines that improve the
capacity of the immune system to build a long standing and
efficient response to antigens. Adjuvants achieve these effects
through different mechanisms, includingmodulation of T helper
subsets.1−4 In the last years, there has been a considerable effort
to introduce a rational approach to the identification of novel
adjuvants that increase safety of vaccines and reinforce the
immune response in weakened immune patients.5−10
A major breakthrough of these studies has been the
identification of pathogen-associated molecular patterns and
the characterization of antigen-presenting cells (APCs) as
convenient targets of novel molecules or delivery systems.11
Sulfavant A (1) is a synthetic sulfolipid that activates human
dendritic cells (DCs), a specific type of APCs that operate as
master regulators of the initiation of adaptive immune response.
Exposure of cultured DC to Sulfavant A (1) triggers the
transformation of DC to the “mature” stage with upregulation of
T-cell co-stimulatory factors (HLA-DR, CD83, CD86) and
expression of specific cytokine subsets (e.g., IL-12p40 and INF-
γ).12 In mice, this process induced antigen-specific immuniza-
tion with antibody titers that are comparable to traditional
adjuvants (e.g., TiterMax). In agreement with these results,
vaccination with hgp10 peptide antigen and Sulfavant A elicited
a protective response with reduction of tumor growth and
increase of survival in the murine B16 melanoma model.12
Although the mechanism has not been fully elucidated,
activity of Sulfavant A (1) is independent of toll-like receptor 2
and 4.12 This marks a clear difference with other glycolipid
adjuvants (e.g., monophosphoryl lipid A) currently under
investigation13−18 and suggests that the sulfoquinovosyl-
glycerol backbone may be a distinctive trait of a novel family
of immunomodulators.19 The aim of the present study was the
additional characterization of the chemical determinants that
affect the biological activity of this group of molecular adjuvants,
as well as the preparation of new analogs with a higher immune
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efficacy. Here, we report a new synthetic strategy of the
sulfolipid scaffold and synthesis of two epimers, named
Sulfavant-S (2) and Sulfavant-R (3), that induce maturation
and cytokine gene expression of DCs at nanomolar concen-
trations. We also show that these compounds form colloidal
nanoparticle aggregates that are first responsible of the
difference in the cellular response to 1−3.
■ RESULTS AND DISCUSSION
Sulfavant A (1) is an epimeric mixture at C-2 (R/S about 1.3:1)
of β-sulfoquinovoside-distearoyl glycerol that is prepared
starting with acetylation of D-glucose, followed by selective
deacetylation of the anomeric hydroxyl group with benzylamine.
Coupling with 1,2-O-isopropylidene glycerol by trichloroaceti-
midate methodology gave 3-O-(2′,3′,4′,6′-tetra-acetyl)-β-D-
glucosyl-glycerol that was after derivatized by stearoyl groups
to obtain the key intermediate 1,2-distearoyl-3-O-β-D-glucosyl
glycerol.12,19 In the original work (route A of Scheme 1),12,19a
sulfonation at carbon-6′ of glucose was achieved by multiple
steps of protection and deprotection that affected negatively the
overall synthetic yield. In order to overtake this issue, we tested
Scheme 1. Improved Synthesis of Sulfavant A (1)
Scheme 2. Synthesis of Sulfavant S (2) and Sulfavant R (3); (a) I2 (1.5 equiv), PPh3 (1,5 equiv), 2,6-Lutidine (22 equiv), 80 °C/
30 min; Ac2O/Pyridine; (b) KSAc (5 equiv), 2-Butanone, 80 °C/2 h; If Not Stated Otherwise, Steps Are Identical to Those
Described in Ref 12
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the direct sulfonation of the 6′-carbon through an iodinate
derivative in agreement with Traboni and co-workers.20
With Sulfavant A (1), iodination of 1,2-distearoyl-3-O-β-D-
glucosyl glycerol followed by conversion to thioacetate reduced
the number of steps from 14 to 11, as well as triplicated the
overall yield from 4 to 11.2% (route B of Scheme 1). The new
approach preserved the versatility of the original synthesis and
was also tested on the preparation of the two epimers Sulfavant S
(2) and Sulfavant R (3) from (S)- or (R)-1,2-O-isopropilidene
glycerol, respectively (Scheme 2).
As depicted in Scheme 2, the single stereoisomers were both
prepared with overall yield higher than 10%. MS and NMR data
of the two new products were identical to Sulfavant A (1) in all
aspects but for the signals of the protons H2-1 that fall at δ 4.40
(1H, dd, J = 2.7, 12.0 Hz, H-1a) and 4.24 (1H, dd, J = 6.9, 12.0
Hz, H-1b) in the S epimer (2) and at δ 4.45 (1H, dd, J = 2.6, 12.1
Hz, H-1a) and 4.17 (1H, dd, J = 6.7, 12.1 Hz, H-1b) in the R
epimer (3) (Figure 1). While the stereochemistry of 3 is
preserved throughout the sequence of reactions, synthesis of 2
showed a partial epimerization of C-2 due to the diaster-
eoselective opening and subsequent closure of the acetonide
during the coupling step. Therefore, Sulfavant S (2) was
composed of a mixture of 4:1 S/R diastereomers at C-2 of
glycerol (Scheme 2) and, in this respect, it was similar to
Sulfavant A (1) but with a different diastereomeric ratio (S/R
about 1:1.3).
The new analogs up-regulated expression of the maturation
markers HLA-DR, CD83, and CD86 at 10 nM (Figure 2). This
was drastically different from the reported response to Sulfavant
A (1) that triggers clear differentiation only of the CD83 + DC
population at 10 μM.12 The activity of both epimers decreased at
the higher concentrations even if Sulfavant S (2) stimulated
residual overexpression of CD83 in the whole range. CD83 is
highly expressed on mature DCs and is not detectable in other
APCs that do not prime naive T cells. Thus, CD83 + DCs are
considered a hallmark of the ability to prime a protective T cell
response and have a profound clinical implication for vaccines
against many widespread infectious diseases, including HIV-
AIDS, malaria, and tuberculosis, or for therapeutic treatment of
cancers.11
After 24 h, compounds 2 and the 3 also enhanced IL-12p40
gene expression (Figure 3) and no effect on expression of IL-10.
IL-12 is a pro-inflammatory cytokine released by DC in response
to infection of bacteria and virus,21,22 whereas IL-10 down-
regulates immune and inflammatory response and mediates
many of the tolerogenic effects exerted by DCs.23,24 On the
whole, the effect of 2 and 3 on these cytokines is qualitatively
similar to the results previously reported with Sulfavant-A (1)
even if the new analogs 2 and 3 gave a maximal activation at 10
nM, whereas 1 showed the strongest effect only at 10 μM.12 As
previously noted for the surface markers, IL-12p40 expression
decreased with the increase of the concentration of both epimers
and only 2 conserved a residual activity at 10 μM. Compounds
1−3 did not show toxic activity on DCs and other primary cells
at concentration up to 105 times higher than the effective dose
(Supporting Information Figure S5).
These tests indicate that 1−3 are all safe DC activators but
also underline a divergent response that correlates with
stereochemical aspects, as the diastereomixture 2 (S/R 4:1)
and the diastereopure 3 are significantly more potent than their
epimeric mixture 1 (S/R about 1:1.3). As reported by diagnostic
expression of CD83 (Figure 4A), efficacy of single epimers 2 and
3 did not increase sigmoidally with concentration but followed a
typical “bell-shaped” curve with decrease of activity above 10
nM. A similar response is also observable with Sulfavant A (1)
but only at a concentration higher than 10 μM. Bell-shaped
dose−response curves are not the rule but several drugs show
this behavior. Recently, occurrence of colloidal species has been
related to the biological response of these products.25 Colloidal
properties are also reported to affect biological activity26−29 and
chemical reactivity30 of sulfoquinovosides in aqueous or polar
environment.
DLS is commonly used for the analysis of supramolecular lipid
aggregation.31 Figure 4B shows the hydrodynamic radius of the
Figure 1. 1HNMR (400MHz, CD3OD/CDCl3 1/1) spectra of 1−3. Partial epimerization of Sulfavant S (2) is clearly detectable by the presence of the
double doublets at 4.45 and 4.17 ppm due to the R epimer.
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aggregates of 1−3 at 0.2 mM in Milli-Q water as measured by
DLS. Sulfavant S (2) and R (3) have a smaller hydrodynamic
radius (around 50 nm), whereas the self-aggregation of Sulfavant
A (1) led to vesicles of 150 nm with higher size dispersity.
Surface tension measurements performed with Sulfavant A, S,
and R (1−3) further highlighted the marked difference between
the aggregation behaviors of these molecules. Indeed, analysis of
the surface tension as a function of concentrations of 1−3
showed a different slope in the premicellar region with
indication of a minimum surface area per molecule (Amin)
larger for Sulfavant A (1) than for Sulfavant S (2) and R (3).
These data proved a different supramolecular organization
among 1−3 in water, as well as a remarkable parallelism between
self-aggregation behavior and biological response. In agreement
with Shoichet and co-workers,25 we suggest that formation of
colloidal particles of Sulfavants reduces the activity because it
affects the effective concentration of the free sulfolipids at the
target site. In line with this view, we suggest that the
concentration of free monomers is higher with the small
colloidal aggregates made by the epimers 2 and 3, whereas it is
lower with the larger aggregates of Sulfavant A (1) (Figure 5).
With the increase of the concentration, the size of both colloid
particles change and the monomers are tied up, thus leading to
the bell-shaped curves measured experimentally around 10 nM
with 2 and 3 and around 10 μM with 1.
Figure 2. Flow-cytometry analysis of maturation phenotyping markers (HLA-DR, CD86, CD83) in moDCs stimulated with (A) Sulfavant A (1), (B)
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■ CONCLUSIONS
Modern vaccines are no longer made with inactivated or
attenuated pathogens, indeed they use pathogen-related
proteins obtained by molecular biology techniques. Therefore,
all vaccines require adjuvants to stimulate innate immune cells
or additional receptors on lymphocytes such as complement
receptors.32 Here, we report an enhancement of the synthesis
and activity of immunomodulatory compounds based on the
sulfoquinovoside-glycerol skeleton. The two new analogs,
Sulfavant S (2) and Sulfavant R (3), trigger maturation of the
innate immune DCs at 10 nM, which is 3 orders of magnitude
lower than the prototype molecule Sulfavant A (1). The increase
of the biological potency correlates with the assembling of
different colloidal particles that is dependent on diasteropurity
of 1−3. We suggest that epimers 2 and 3 can form aggregates
smaller and less “cohesive”, thus in equilibrium with a “more
effective” fraction of monomers that can freely diffuse and
interact with cell targets. The colloid hypothesis also well
explains the bell-shaped dose−response curve that seems to be
typical of this family of compounds. Notably, it has been already
reported that stereochemical characteristics can determine the
supramolecular organization of amphipathic substances and
change the biological activity by interfering with interaction and
binding affinity with protein and cellular structures.33−37 DCs
are emerging as a critical cell type in controlling the immune
response; therefore, the stimulation of DC by Sulfavants must be
considered a promising feature to generate therapeutic vaccines
and, in view of in vivo tests, the formation of stable self-
aggregates and the absence of in vitro toxic effects are predictive
of a low level of toxicological risk.
■ EXPERIMENTAL SECTION
General Experimental Procedures. NMR spectra were
recorded on a Bruker AVANCE-400 (400.13 MHz). HR-MS
spectra were acquired by a Q Exactive Hybrid Quadrupole-
Orbitrap mass spectrometer (Thermo Scientific). TLC plates
(Kieselgel 60 F254) and silica gel powder (Kieselgel 60, 0.063−
0.200 mm) were from Merck.
All the reagents were purchased from Sigma-Aldrich and used
without any further purification. DLS measurements were
performed with a home-made instrument composed by a
Photocor compact goniometer, an SMD 6000 Laser Quantum
50 mW light source operating at 5325 Å, a photomultiplier
(PMT-120-OP/B), and a correlator (Flex02-01D, correlator.-
com). The surface tension of aqueous Sulfavant samples was
measured with a Sigma 70 tensiometer (KSV, Stockholm,
Sweden) using the Du Noüy ring method.
1,2-O-Isopropilidene-3-O-[(2′,3′,4′,6′-tetra-O-acetyl)-
β-D-glucosyl]-S-glycerol. 1H NMR (400 MHz, CDCl3): δ
5.19 (1H, bt, J = 9.4 Hz, H-3′), 5.06 (1H, bt, J = 9.9 Hz, H-4′),
4.99 (1H, bt, J = 8.4 Hz, H-2′), 4.60 (1H, d, J = 7.8 Hz, H-1′),
4.25 (1H, dd, J = 5.0, 12 Hz, H-1a), 4.14−3.69 (6H, overlapped,
H-1b, H-2, H2-6′, H-5′, H-3a), 3.62 (1H, dd, J = 5.9, 10.7 Hz, H-
3b), 2.08 (3H, s, OAc), 2.04 (3H, s, OAc), 2.01 (3H, s, OAc),
1.99 (3H, s, OAc), 1.40 (3H, s, CH3), 1.33 (3H, s, CH3); the
spectrum 1H NMR showed traces of signals related to the
epimer R; HRESIMS m/z: 485.1639 [M + Na]+ (calcd for
C20H30O12Na, 485.1635).
1,2-Di-O-stearoyl-3-O-β-D-glucosyl-S-glycerol. 1H
NMR (400 MHz, CDCl3): δ 5.24 (1H, m, H-2), 4.38 (1H,
dd, J = 2.5, 12.0 Hz, H-1a), 4.29 (1H, d, J = 7.5 Hz, H-1′), 4.16
(1H, dd, J = 6.7, 12.0 Hz, H-1b), 3.88 (1H, dd, J = 5.1, 10.6 Hz,
H-3a), 3.81 (2H, m, H2-6′), 3.68 (1H, dd, J = 6.9, 10.6 Hz, H-
3b), 3.55 (1H, bt, J = 9.1 Hz, H-3′), 3.49 (1H, bt, J = 9.1 Hz, H-
4′), 3.34 (1H, bt, J = 8.0 Hz, H-2′), 3.29 (1H, m, H-5′), 2.28
(4H, overlapped, α-methylenes of acyl portions), 1.65−1.52
(4H, overlapped, β-methylenes of acyl portions), 1.33−1.19
(aliphatic methylenes), 0.86 (6H, bt, J = 6.3 Hz, 2CH3); the
spectrum 1H NMR showed traces of signals related to the
epimer R; HRESIMS m/z: 809.6116 [M + Na]+ (calcd for
C45H86O10Na, 809.6119).
1,2-Di-O-stearoyl-3-O-[(2′,3′,4′-tri-O-acetyl-6′-thioa-
cetyl)-β-D-glucosyl]-S-glycerol. 1H NMR (400 MHz,
CDCl3): δ 5.19−5.10 (2H, overlapped, H-2, H-3′), 4.97−4.88
(2H, overlapped, H-2′, H-4′), 4.47 (1H, d, J = 8.0 Hz, H-1′),
Figure 3. Gene expression analysis of IL-12p40 in DCs by stimulation
with increasing dose of Sulfavants 1−3. Asterisks indicate significant
differences from the control group at a 95% (P < 0.05) confidence level,
as determined using two-way ANOVA analysis.
Figure 4.Correlation of immunomodulatory activity vs colloidal behavior of Sulfavants 1−3. (A) Percentage of mature DCs after stimulation by 1−3.
Data are expressed as mean and standard deviation from a duplicate of two independent experiments and compared to cells treated only with vehicle
(Ctrl). ****P< 0.0001 vs control. (B)Hydrodynamic radius distribution of particles of 1−3 in aqueous suspension at 0.2mM asmeasured by dynamic
light scattering (DLS) on three independent measurements. Red = Sulfavant A (1); blue = Sulfavant S (2); green = Sulfavant R (3).
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4.27 (1H, dd, J = 3.5, 10.0 Hz, H-1a), 4.09 (1H, dd, J = 6.4, 10.0
Hz, H-1b), 3.88 (1H, dd, J = 4.7, 11.0 Hz, H-3a), 3.64 (1H, dd, J
= 5.3, 11.0 Hz, H-3b), 3.60 (1H, m, H-5′), 3.22 (1H, dd, J = 2.4,
14.3 Hz, H-6′a), 3.03 (1H, dd, J = 6.9, 14.3 Hz, H-6′b), 2.32
(3H, s, SAc), 2.27 (4H, bt, J = 7.0 Hz, α-methylenes of acyl
portions), 2.05 (3H, s, OAc), 2.01 (3H, s, OAc), 1.96 (3H, s,
OAc), 1.63−1.54 (4H, overlapped, β-methylenes of acyl
portions), 1.32−1.19 (aliphatic methylenes), 0.85 (6H, bt, J =
6.2 Hz, 2CH3); the spectrum
1H NMR showed traces of signals
related to the epimer R; HRESIMS m/z: 993.6302 [M + Na]+
(calcd for C53H94NaO13S, 993.6313).
1,2-O-Isopropilidene-3-O-[(2′,3′,4′,6′-tetra-O-acetyl)-
β-D-glucosyl]-R-glycerol. 1H NMR (400 MHz, CDCl3): δ
5.13 (1H, bt, J = 9.4 Hz, H-3′), 4.99 (1H, bt, J = 9.8 Hz, H-4′),
4.89 (1H, bt, J = 8.4 Hz, H-2′), 4.53 (1H, d, J = 7.8 Hz, H-1′),
4.18−3.95 (3H, overlapped, H2-1, H-2) 3.72−3.51 (5H,
overlapped, H2-6′, H-5′, H2-3), 2.00 (3H, s, OAc), 1.97 (3H,
s, OAc), 1.94 (3H, s, OAc), 1.92 (3H, s, OAc), 1.35 (3H, s,
CH3), 1.30 (3H, s, CH3); HRESIMS m/z: 485.1641 [M + Na]
+
(calcd for C20H30O12Na, 485.1635).
1,2-Di-O-stearoyl-3-O-β-D-glucosyl-R-glycerol. 1H
NMR (400 MHz, CDCl3): δ 5.25 (1H, m, H-2), 4.34 (1H,
dd, J = 2.7, 12.0 Hz, H-1a), 4.26 (1H, d, J = 7.5 Hz, H-1′), 4.10
(1H, dd, J = 6.7, 12.0 Hz, H-1b), 3.87 (1H, dd, J = 5.9, 11.0 Hz,
H-3a), 3.77 (2H, overlapped, H2-6′), 3.67 (1H, dd, J = 5.9, 11.0
Hz, H-3b), 3.47 (1H, bt, J = 8.9 Hz, H-3′), 3.42 (1H, bt, J = 8.9
Hz, H-4′), 3.25−3.20 (2H, overlapped, H-2′, H-5′), 2.26 (4H,
overlapped, α-methylenes of acyl portions), 1.58−1.51 (4H,
overlapped, β-methylenes of acyl portions), 1.27−1.18
(aliphatic methylenes), 0.83 (6H, bt, J = 6.4 Hz, 2CH3);
HRESIMS m/z: 809.6112 [M + Na]+ (calcd for C45H86O10Na,
809.6119).
1,2-Di-O-stearoyl-3-O-[(2′,3′,4′-tri-O-acetyl-6′-thioa-
cetyl)-β-D-glucosyl]-R-glycerol. 1H NMR (400 MHz,
CDCl3): δ 5.18−5.11 (2H, overlapped, H-2, H-3′), 4.98−4.91
(2H, overlapped, H-4′, H-2′), 4.47 (1H, d, J = 8.0 Hz, H-1′),
4.27 (1H, dd, J = 3.8, 12.0 Hz, H-1a), 4.07 (1H, dd, J = 6.3, 12.0
Hz, H-1b), 3.90 (1H, dd, J = 4.9, 11.0 Hz, H-3a), 3.65 (1H, dd, J
= 5.6, 11.0 Hz, H-3b), 3.62 (1H, m, H-5′), 3.24 (1H, dd, J = 2.7,
14.0 Hz, H-6′a), 3.05 (1H, dd, J = 6.9, 14.0 Hz, H-6′b), 2.33
(3H, s, SAc), 2.32−2.26 (4H, overlapped, α-methylenes of acyl
portions), 2.10−1.98 (9H, s, 3OAc), 1.63−1.56 (4H, m, β-
methylenes of acyl portions), 1.32−1.20 (aliphatic methylenes),
0.87 (6H, bt, J = 6.5Hz, 2CH3); HRESIMSm/z: 993.6321 [M+
Na]+ (calcd for C53H94NaO13S, 993.6313).
1,2-Di-O-stearoyl-3-O-[(2′,3′,4′-tri-O-acetyl-6′-iodo)-
β-D-quinovosyl]-R/S-glycerol (4). Iodine (49 mg, 0.191
mmol) was added to a mixture of 1,2-distearoyl-3-O-β-D-
glucosyl glycerol (100 mg, 0.127 mmol), triphenylphosphine
(50 mg, 0.191 mmol), and 2,6-dimethylpyridine (450 mg, 4.2
mmol) at temperature of 80 °C; the mixture was stirred for 30
min at 80 °C and subsequently acetylated by addition of pyridine
(0.5mL) and acetic anhydride (0.5mL); after evaporation of the
solvent under a stream of nitrogen, the mixture was purified by
silica gel chromatography using a gradient of petroleum ether/
diethylether to give compound 4 (195 mg, 0.191 mmol, 100%)
as a colorless oil; 1H NMR (400 MHz, CDCl3): δ 5.21−5.16
(2H, overlapped, H-2, H-3′), 4.99−4.94 (1H, m, H-2′), 4.87 (t,
J = 8.03 Hz, H-4′), 4.56 and 4.55 (each 1H, d, J = 8.1 Hz, H-1′ of
the two epimers), 4.33−428 (1H, m, H-1a), 4.17−4.09 (1H, m,
Figure 5.Representation of the proposed colloidal mechanism of action of Sulfavants. Self-association of the sulfolipids into colloidal particles depends
on diasteropurity of the organic molecules. With epimers 2 and 3 (left side), the concentration of free monomers in equilibriumwith small aggregates is
high and the products occupy effectively the receptor target at very low dose (EC50 10 nM). With the increase of the concentration, there is a gradual
loss of the activity leading to a typical bell-shaped dose response curve that we attribute to occurrence of larger colloidal nanoparticles. The epimeric
mixture 1 (right side) produces large aggregates that are able to hold themonomers, thus reducing the effective concentration of themonomers and the
biological potency (EC50 10 μM). Increase of the concentration of 1 induces loss of activity for the formation of very large aggregates that cannot
interact with the cell target in an effective manner. At the moment, we have no direct cue to explain the dependence of the size of the colloidal
aggregates on the diastereomeric purity of the glycerol center. However, it is reasonable that the presence of both epimers can break the symmetry of
the packing of the alkyl chains, thus leading to less dense and less tightly packed structures.
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H-1b), 4.02−3.97 (1H, m, H-3a), 3.78−3.71 (1H, m, H-3b),
3.52 (1H, m, H-5′), 3.28 (1H, dd, J = 3.06, 11.1 Hz, H-6′a), 3.13
(1H, dd, J = 8.4, 11.1Hz, H-6′b), 2.35−2.26 (4H, overlapped, α-
methylenes of stearoyl portions), 2.07−1.97 (9H, s, OAc),
1.64−1.58 (4H, overlapped, β-methylenes of stearoyl portions),
1.33−1.21 (60H, aliphatic methylenes), 0.91−0.84 (6H,
overlapped, 2CH3); HRESIMS m/z: 1045.5460 [M + Na]
+
(calcd for C51H91NaO12I, 1045.5453).
1,2-Distearoyl-3-O-[(2′,3′,4′-tri-acetyl-6′-thioacetyl)-
β-D-glucosyl]-R/S-glycerol (5). 1,2-distearoyl-3-O-[(2′,3′,4′-
tri-acetyl-6′-iodo)-β-D-glucosyl]-glycerol (4) (170 mg, 0.166
mmol) was dissolved in 2-butanone (15 mL) and potassium
thioacetate (94 mg, 0.830 mmol). The reaction mixture was
stirred at 80 °C for 2 h, and then, the solvent was evaporated
under reduced pressure. The resulting material was purified by
silica gel chromatography using a light petroleum ether/diethyl
ether gradient to give 1,2-distearoyl-3-O-[(2′,3′,4′-tri-acetyl-6′-
thioacetyl)-β-D-glucosyl]-glycerol (161 mg, 0.166 mmol, 100%)
as a colorless oil; 1H NMR (400 MHz,CDCl3): δ 5.20−5.14
(2H, m, H-2, H-3′), 4.96−4.89 (2H, m, H-2′, H-4′), 4.50 (1H,
d, J = 8.0 Hz, H-1′), 4.28 (1H, dd, J = 4.1, 11.8 Hz, H-1a), 4.09
(1H, dd, J = 5.7, 11.8 Hz, H-1b), 3.91 (1H, dd, J = 4.5, 11.1 Hz,
H-3a), 3.65 (1H, dd, J = 5.4, 11.1Hz, H-3b), 3.62 (1H,m,H-5′),
3.25 (1H, bd, J = 11.4 Hz, H-6′a), 3.06 (1H, dd, J = 2.4 Hz, 11.4
Hz), 2.35 (3H, s, SAc), 2.33−2.29 (4H, m, α-methylene of
stearoyl portion), 2.13−1.99 (9H, s, 3OAc), 1.64−1.57 (4H, m,
β-methylene of stearoyl portion), 1.32−1.23 (60H, aliphatic
methylenes), 0.93−0.87 (6H, overlapped, 2CH3); HRESIMS
m/z: 993.6329 [M +Na]+ (calcd for C53H94O13NaS, 993.6313).
Sulfavant S (2).White solid; 1HNMR (400MHz, CD3OD/
CDCl3 1/1): δ values are referred to CHD2OD (3.34 and 49.0
ppm): 5.28 (1H, m, H-2), 4.40 (1H, dd, J = 2.7, 12.0 Hz, H-1a),
4.31 (1H, d, J = 7.6 H-1′), 4.24 (1H, dd, J = 6.9, 12.0 Hz, H-1b),
4.05 (1H, dd, J = 5.4, 11.0 Hz, H-3a), 3.79−3.71 (3H, H-3b, H-
3′, H-4′), 3.41 (1H, bt, J = 8.9 Hz, H-2′), 3.26 (1H, H-6′a), 3.25
(1H, H-5′), 3.09 (1H, dd, J = 7.2, 15.7 Hz, H-6′b), 2.36−2.27
(4H, α-methylenes of stearoyl portions), 1.65−1.56 (4H, β-
methylenes of stearoyl portions), 1.36−1.20 (60H, aliphatic
methylenes), 0.89 (6H, bt, J = 6.0 Hz, 2CH3);
13C NMR (100
MHz, CD3OD/CDCl3 1/1): δ 174.1, 173.7 (C, acyl esters of
stearoyl part), 103.2 (CH, C1′), 76.1 (CH, C2′), 73.8 (CH,
C5′), 72.4 (CH, C3′), 72.3 (CH, C4′), 70.2 (CH, C2), 68.2
(CH2, C3), 63.2 (CH2, C1), 53.6 (CH2, C6′), 34.2 (CH2, α-
methylene of stearoyl portion), 32.2−29.0 (CH2, methylenes of
stearoyl portion), 24.9 (CH2, β-methylene of stearoyl portion),
13.8 (CH3, methyls of stearoyl portion); HRESIMS m/z:
849.5772 [M − K]− (calcd for C45H85O12S−, 849.5767).
Sulfavant R (3).White solid; 1HNMR (400MHz, CD3OD/
CDCl3 1/1): δ values are referred to CHD2OD at 3.34 and 49.0
ppm): δ 5.28 (1H, m, H-2), 4.45 (1H, dd, J = 2.6, 12.1 Hz, H-
1a), 4.31 (1H, d, J = 7.7Hz, H-1′), 4.17 (1H, dd, J = 6.7, 12.1Hz,
H-1b), 4.05 (1H, dd, J = 5.2, 11.1 Hz, H-3a), 3.78−3.71 (3H,
overlapped, H-3b, H-3′, H-4′), 3.40 (1H, bt, J = 8.7 Hz, H-2′),
3.26 (1H, H-5′), 3.24 (1H, H-6′a), 3.09 (1H, dd, J = 7.2, 15.7
Hz, H-6′b), 2.35−2.29 (4H, α-methylenes of stearoyl portions),
1.64−1.57 (4H, β-methylenes of stearoyl portions), 1.32−1.22
(60H, aliphatic methylenes), 0.88 (6H, bt, J = 6.9 Hz, 2CH3);
13C NMR (100 MHz, CD3OD/CDCl3 1/1): δ 174.0, 173.8 (C,
acyl esters of stearoyl part), 103.1 (CH, C1′), 76.3 (CH, C2′),
73.5 (CH, C5′), 72.3 (CH, C3′), 72.2 (CH, C4′), 70.5 (CH,
C2), 68.1 (CH2, C3), 63.1 (CH2, C1), 53.2 (CH2, C6′), 34.1
(CH2, α-methylene of stearoyl portion), 32.5−29.2 (CH2,
methylenes of stearoyl portion), 24.8 (CH2, β-methylene of
stearoyl portion), 13.7 (CH3, methyls of stearoyl portion);
HRESIMS m/z: 849.5775 [M − K]− (calcd for C45H85O12S−,
849.5767).
Characterization of Colloidal Nanoparticles. After
purification by high-performance liquid chromatography,
samples were prepared in 1 mL of Millipore water at 0.2 mM
(170 μg) of each compound. After sonication for 40 min at 35
°C, the solutions were maintained at room temperature (20 °C)
for 24 h. The mean diffusion coefficient was obtained as an
average of at least three measurements at 25 °C. Stability of the
systems over time (1 week) was systematically controlled by the
reproducibility of the diffusion coefficients.
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